Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18933499 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933567 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933750 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933645 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18889137 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18807591 | COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSION | August 2024 | November 2024 | Allow | 3 | 0 | 1 | No | No |
| 18586689 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | February 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18393408 | miRNA Switches for RNA-Triggered Control of RNA Interference | December 2023 | March 2025 | Allow | 15 | 3 | 0 | Yes | No |
| 18518177 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | November 2023 | February 2025 | Allow | 15 | 3 | 1 | Yes | No |
| 18504827 | MICROORGANISMS AND USES THEREOF | November 2023 | January 2025 | Abandon | 14 | 1 | 1 | No | No |
| 18362675 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | July 2023 | May 2025 | Abandon | 22 | 3 | 1 | Yes | No |
| 18343014 | RNA AND DNA ANALYSIS USING ENGINEERED SURFACES | June 2023 | December 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18144276 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18040302 | COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSION | February 2023 | June 2025 | Allow | 28 | 1 | 1 | No | No |
| 17679977 | CODON-OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING AN AP-1 TRANSCRIPTION FACTOR | February 2022 | November 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17675229 | METAL ION-START DNA POLYMERASE SWITCH AND ISOTHERMAL POLYMERASE AMPLIFICATION METHOD USING THE SAME | February 2022 | August 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17583594 | Reporting Construct with Synaptobrevin Based Moiety | January 2022 | December 2024 | Allow | 35 | 2 | 0 | No | No |
| 17582594 | SOLUTE CARRIER FAMILY 46 MEMBER 3 (SLC46A3) AS MARKER FOR LIPID-BASED NANOPARTICLE CANCER THERAPY AND DIAGNOSTICS | January 2022 | October 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17604880 | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17593826 | RNAI MOLECULE | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17441905 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | September 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17441620 | METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17440139 | RSK INHIBITORS IN THE TREATMENT OF VIRUS DISEASES | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17421277 | A METHOD OF TREATING CYSTIC FIBROSIS | July 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17420808 | TREATMENT OF FATTY LIVER DISEASE | July 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17312740 | CONTROL OF INSECT INFESTATION | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17311175 | ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9 | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17299355 | Cyclic Di-Nucleotide Compounds as STING Agonists | June 2021 | March 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17296163 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17290582 | NEW THERAPY | April 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17245443 | ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1 | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17282340 | OLIGONUCLEOTIDE MEDIATED NO-GO DECAY | April 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17204008 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17275132 | L-OLIGONUCLEOTIDE INHIBITORS OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) | March 2021 | June 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17196531 | RNAI INDUCED C9ORF72 SUPPRESSION FOR THE TREATMENT OF ALS/FTD | March 2021 | October 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17271549 | SYSTEMS AND METHODS RELATED TO OLIGONUCLEOTIDE BUFFERS | February 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17269488 | FACTOR IX ENCODING NUCLEOTIDES | February 2021 | September 2024 | Allow | 43 | 2 | 0 | No | No |
| 16973908 | COMPLEX FOR THE DELIVERY OF CAS9 PROTEINS AND GUIDE RNA TO CELLS | December 2020 | June 2025 | Abandon | 54 | 0 | 1 | No | No |
| 17052508 | REVERSE TRANSCRIPTASE SEQUENCE OF MARINE BACTERIOPHAGE AND USE THEREOF | November 2020 | June 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16982977 | Immortalization of Splenic and Peripheral Blood Macrophages Using a Multi-Cistronic V-RAF/V-MYC Lentivirus | September 2020 | March 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 16901514 | BACTERIAL QUANTITATIVE TRAIT-LOCUS MAPPING | June 2020 | March 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 16760868 | CHEMICALLY-MODIFIED GUIDE RNAS TO IMPROVE CRISPR-CAS PROTEIN SPECIFICITY | April 2020 | May 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16781891 | ALGORITHMS FOR DISEASE DIAGNOSTICS | February 2020 | May 2025 | Abandon | 60 | 1 | 1 | No | No |
| 16748267 | Method for Fragmenting Genomic DNA Using CAS9 | January 2020 | January 2025 | Abandon | 60 | 2 | 0 | No | No |
| 16560685 | Increasing Cellular Lipid Production by Increasing the Activity of Diacylglycerol Acyltransferase and Decreasing the Activity of Triacylglycerol Lipase | September 2019 | April 2025 | Abandon | 60 | 2 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ZAHORIK, AMANDA MARY works in Art Unit 1636 and has examined 38 patent applications in our dataset. With an allowance rate of 31.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner ZAHORIK, AMANDA MARY's allowance rate of 31.6% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZAHORIK, AMANDA MARY receive 1.18 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by ZAHORIK, AMANDA MARY is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +75.1% benefit to allowance rate for applications examined by ZAHORIK, AMANDA MARY. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 41.7% of applications are subsequently allowed. This success rate is in the 92% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 16.7% are granted (fully or in part). This grant rate is in the 8% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.